Novel Carbon Dots Derived from Moutan Cortex Significantly Improve the Solubility and Bioavailability of Mangiferin

Chuihao Kong¹,²,* Kaidi Wang¹,²,* Lei Sun¹,³ Hongsu Zhao¹,² Tongsheng Wang¹ Wuxi Zhou¹, Deling Wu¹,² Fengqing Xu¹,²

¹School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, People’s Republic of China; ²Anhui Province Key Laboratory of New Manufacturing Technology for Traditional Chinese Medicine Decoction Pieces, Hefei, 230012, People’s Republic of China; ³Zhejiang CONBA Pharmaceutical Co. LTD, Hangzhou, 310052, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Wuxi Zhou; Fengqing Xu, School of Pharmacy, Anhui University of Chinese Medicine, 350 Longzhu Road, Xinzhan District, Hefei, 230012, People’s Republic of China, Email zhouwuxi@ahtcm.edu.cn; xufengqing@ahtcm.edu.cn

Background: Mangiferin (MA), a bioactive C-glucosyl xanthone with a wide range of interesting therapeutic properties, has recently attracted considerable attention. However, its application in biomedicine is limited by poor solubility and bioavailability. Carbon dots (CDs), novel nanomaterials, have immense promise as carriers for improving the biopharmaceutical properties of active components because of their outstanding characteristics.

Methods: In this study, a novel water-soluble carbon dot (MC-CDs) was prepared for the first time from an aqueous extract of Moutan Cortex Carbonisata, and characterized by various spectroscopies, zeta potential and high-resolution transmission electron microscopy (HRTEM). The toxicity effect was investigated using the CCK-8 assay in vitro. In addition, the potential of MC-CDs as carriers for improving the pharmacokinetic parameters was evaluated in vivo.

Results: The results indicated that MC-CDs with a uniform spherical particle size of 1–5 nm were successfully prepared, which significantly increased the solubility of MA in water. The MC-CDs exhibited low toxicity in HT-22 cells. Most importantly, the MC-CDs effectively affected the pharmacokinetic parameters of MA in normal rats. UPLC-MS analysis indicated that the area under the maximum blood concentration of MA from mangiferin-MC-CDs (MA-MC-CDs) was 1.6-fold higher than that from the MA suspension liquid (MA control) after oral administration at a dose of 20 mg/kg.

Conclusion: Moutan Cortex-derived novel CDs exhibited superior performance in improving the solubility and bioavailability of MA. This study not only opens new possibilities for the future clinical application of MA but also provides evidence for the development of green biological carbon dots as a drug delivery system to improve the biopharmaceutical properties of insoluble drugs.

Keywords: Moutan Cortex, carbon dots, mangiferin, solubility, bioavailability

Introduction
Mangiferin (MA), a natural C-glucosyl xanthone scaffold initially isolated from Mangifera indica, exhibits a wide range of interesting pharmacological activities, such as cardioprotective, immunomodulatory, antioxidant, antitumor, antidiabetic, and anti-inflammatory effects.¹–⁷ The therapeutic significance of MA has made it attractive for the research and development of drugs and food supplements over decades. Nonetheless, some limitations caused by the structural type of xanthone C-glycoside, including scarce solubility in water and low bioavailability, severely restrict its clinical applications.⁸ Currently, several studies on solubilization methods have been conducted to improve the water solubility and bioavailability of MA, but there is still a lack of satisfactory outcome.⁹–¹⁶ Therefore, developing new materials and
techniques to improve MA’s biopharmaceutical properties of MA is a challenging issue and requires a considerable amount of effort.

The hydrophilicity and bioavailability of insoluble active components can be improved by making into nanomaterials which are a special class of materials with unique physical, chemical, and biological properties.17–20 Many studies have aimed at developing novel nanomaterial-based sensors for applications in biology and medicine, while their clinical applications are greatly restricted by high cost and adding highly toxic components.21–23 As novel nanomaterials, carbon dots (CDs) have gained particular attention in recent years owing to their outstanding characteristics and wide-ranging pharmaceutical applications.24–38 In particular, their small size and large surface area make them highly water-soluble and biocompatible, which holds great promise for drug delivery. However, most CDs are chemically synthesized derivatives using multiple materials which biocompatibility and biological security falls short of that of natural sources.39–41 Moutan Cortex (MC), a well-known Traditional Chinese Medicine, has a long history of medical applications in China and other Asian countries. Modern studies have shown that MC has antioxidant, anti-cancer, hypoglycemic, anti-aggregatory, anti-inflammatory, and antiallergic properties, and other effects.42–46 The structures in MC make it advantageous for the formation of nanoclusters.47 Recently, we made an interesting discovered that a novel carbon dot (MC-CDs) derived from MC, the only source, exhibited significant potential for applications in biology and medicine, and further proposed the hypothesis that MC-CDs can serve as a natural carrier, holding potential for improving the solubility and bioavailability of MA.

In this study, for the first time, we evaluated the Moutan Cortex-carbon dots in particle size, structural details, fluorescence behavior, elemental composition, and surface functional groups. The biopharmaceutical properties were investigated in vivo and in vitro and showed superior performance in terms of improving the solubility and bioavailability of MA. This study not only opens new possibilities for the future clinical application of MA but also provides evidence for the development of green biological carbon dots as a drug delivery system to improve the biopharmaceutical properties of insoluble drugs.

**Materials and Methods**

**Materials and Chemicals**

The root bark of *Paeonia ostii* was collected from Anhui Tongling Hetian Traditional Chinese Medicine Pieces Co., Ltd. and identified by associate-Prof. QingShan Yang, Anhui University of Traditional Chinese Medicine. MC-CDs were prepared in our laboratory. MA and isomangiferin with a purity > 98.0% were provided by Wuhan ChemFace.
Biotechnology Co., Ltd., and a dialysis bag with a molecular mass of 3000 Da was purchased from Sigma-Aldrich St. Louis. All chemical reagents were of chromatographic or analytical grade.

Animals
Male Sprague-Dawley rats (weighing 200 ± 20 g) were obtained from Animal Certificate No. SCXK (Lu) 2019–0003 was purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. (Jinan, China). After 1 week of feeding, the animal experiments were performed according to the animal protocol of the Animal Ethics Association of Anhui University of Chinese Medicine (Ethics number: AHUCM-rats-2022104).

Preparation of MC-CDs
Carbonized *Moutan Cortex* was obtained by pyrolysis method (Figure 1). Briefly, an open crucible containing the dry root bark of *P. ostii* was wrapped in aluminum foil, sealed with a lid, and placed in a muffle furnace (KSL-1700X, Hefei Kejing Material Technology Co., Ltd.). The carbonized *Moutan Cortex* was obtained according to the following procedure: the temperature was raised to 350°C within an hour, insulated for 1 h, and then cooled to room temperature. The carbonized product was crushed into powder, placed in a beaker, and extracted three times with deionized water (10 times, 2 h each) at 100°C. The filtrate was concentrated using a rotary evaporator, and the concentrated liquid was centrifuged at 5000 rpm for 10 min to remove the insoluble material and then loaded into the treated 3000 Da dialysis bag. The water was changed after some time, and dialysis was carried out for 4 days. The dialysis inner liquid was freeze-dried to obtain *Moutan Cortex*-Carbon dots (MC-CDs).

Characterization Study of MC-CDs
TEM analysis was performed using a Talos F200X electron microscope (Thermo Fisher Scientific). HRTEM was performed using a JEM-2100 Transmission electron microscope (JEOL, Japan) to determine the dispersion and morphology of CDs. IR spectra were obtained on a Nicolet 6700 FT-IR spectrometer (Thermo Fisher Scientific, USA) with KBr pellets in the range 4000–1000 cm⁻¹. Absorption and fluorescence measurements were performed using a UV-visible spectrophotometer (Specord S600, Analytik JENA, Germany) and F-450 fluorescence spectrophotometer (Toyko, Japan). The determination of the atoms contained in the carbon quantum dots of MC and their percentage contents were verified via X-ray photoelectron spectroscopy (XPS, ESCALAB 250, Thermo Fisher Scientific), X-ray diffraction (XRD) was performed with X-ray diffractometer (SmartLab). Zeta potential was carried out on Zetasizer Nano ZS (Malvern Panalytical Ltd.). All statistical graphs were made in Origin 2021 software.

![Figure 1 Preparation scheme of Moutan Cortex-Carbon dots (MC-CDs).](image-url)
Measurement of Fluorescence Quantum Yields

Fluorescence quantum yield was acquired according to a method described as reported. Briefly, Quinine sulfate was used as the control standard (quantum yield 54% in 0.1 M sulfuric acid solution). The absorbance of the aqueous solution of the MC-CDs and control sample was maintained below 0.10 at 350 nm. The fluorescence yield was determined by integrating the established procedure. The fluorescence quantum yield was calculated using the following equation:

$$\theta_t = \theta_c \times \frac{A_t}{A_c} \times \frac{I_t}{(n_t)^2} \times \frac{(n_c)^2}{I_c}$$

where “θ” is the fluorescence quantum yield, “A” is the absorbance at the excitation wavelength (350 nm), and “I” is the refractive index of the solvent, the subscripts “t” and “c” refer to the test (MC-CDs) and the standard (quinine sulfate), respectively.

Cytotoxicity Assays

HT-22 cells were cultured at 37°C in 5% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Inc., NY, USA) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS; Gibco Inc., NY, USA). The MC-CDs were dissolved in deionized water and diluted with the cell culture medium to obtain the desired concentrations. The cells were seeded into 96-well plates at a density of 1×10⁵ cells/well and incubated with 10% fetal bovine serum medium and different concentrations of MC-CDs. After incubation for 24 h, cell survival was determined using the CCK-8 method.

Water Solubility Assay

First, MA (3.2 mg) and isomangiferin (3.0 mg) were placed in 10 mL volumetric flasks, dissolved in ultrapure water, sonicated, and centrifuged to prepare saturated aqueous solutions of standards. The saturated solution was transferred and diluted 10-, 50-, 100, and 500 times to get the corresponding sample solutions to measure their water solubility. Subsequently, the concentration of MC-CDs (30 mg dissolved in 10 mL aqueous solution) was diluted to 10 grades in the concentration range of 1500 to 3.12 μg/mL. Next, in a 5 mL EP tube, 2 mg of MA or isomangiferin was accurately weighed, and then 1mL corresponding concentration of the MC-CDs solution was added, which resulted in a mixed saturated solution after sonication in an ultrasonic cleaner at 480 W for 30 min. The obtained solution was centrifuged at 10000 rpm for 10 min, and the supernatant was collected and filtered through a 0.22 μm membrane prior to injection. Chromatographic analyses of all the standards and samples were performed a Shimadzu 2030 C HPLC instrument (Shimadzu, Japan). Chromatographic separation was carried out at 30°C on a Phenomenex-C18 column (250 mm ×4.6 mm, 5 μm, USA), and eluted with 0.4% glacial acetic acid water (A)-acetonitrile (B) = 85:15, at 1.0 mL/min. Every 20 μL solution was injected for each run, and the PDA spectra were recorded at 318 nm. Calibration curves and methodological investigation experiments were performed according to the methods of the Chinese Pharmacopoeia.

Pharmacokinetic Experiments

MA was added to an aqueous solution of MC-CDs and stirred for 20 min to obtain a saturated suspension of mangiferin-MC-CDs (MA-MC-CDs). MA was dissolved in an aqueous solution to obtain an MA suspension liquid (MA control). Rats were fasted, but provided free drinking 12 h prior to drug administration. MA-MC-CDs (2 mg/mL) and the MA control (2 mg/mL) were administered via oral gavage at a dose of 20 mg/kg. 0.5 mL blood was collected from the orbit at each time point of 5 min, 15 min, 30 min, 45 min, 60 min, 120 min, 240 min, 480 min, 720 min, 1440 min. Blood was placed in an EP tube containing heparin sodium, centrifuged at 4000 rpm for 5 min, and plasma was obtained. A 400 μL mixture solution of acetonitrile and glacial acetic acid at a ratio of 9:1 (v:v) was added to 100 μL plasma, vortexed, and centrifuged at 10000 rpm for 10 min, and the supernatant was collected and evaporated using liquid nitrogen to obtain the dry residue. The residues and the internal standard (isomangiferin) were dissolved in the mobile phase and centrifuged at 10,000 rpm for 10 min. The obtained supernatant was analyzed using a SCIEX TRIPLE QUAD 4500 Triple Quadrupole Series Mass Spectrometer (UHPLC-QTRAP-MS/MS, AB SCIEX, USA).
Chromatographic separation was carried out at 30°C on a ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm × 1.7 μm), and eluted with 0.4% glacial acetic acid water (A)-acetonitrile (B) = 90:10, at 0.2 mL/min. Every 3 μL of the solution was injected for each run, and the total ion chromatogram (TIC) was recorded at DP: −38V and CE: −32V.

Statistical Analysis
The data were presented as mean ± S.D. All values were analyzed using a one-way analysis of variance (ANOVA) and LSD- t test by IBM SPSS Statistics 23.0. The statistical graphs were generated using Graph-Pad Prism 8.0 software and Origin 2021. P values < 0.05 were considered statistically significant.

Results

Characteristics of MC-CDs
The TEM image of the MC-CDs (Figure 2A) revealed that they were nearly spherical with a size distribution in the range of 1–5 nm (Figure 2B). Furthermore, the HRTEM (Figure 2C) showed that the CDs have a lattice spacing of 0.10 nm (Figure 2D). The UV-vis spectrum (Figure 2E) of the aqueous MC-CDs solution exhibited a broad absorption spectrum at 200–300 nm. The photoluminescence spectra of the MC-CDs in aqueous solutions exhibited the strongest emission at approximately 445 nm, with the strongest excitation at 350 nm. XRD analysis confirmed the amorphous nature of prepared MC-CDs. A broad peak at 2θ = 22.1° was exhibited in the XRD pattern of MC-CDs (Figure 2G), indicating the presence of crystal planes of graphitic carbon (002) in MC-CDs. In addition, some weak peaks can be observed. The crystal plane 110 at 2θ = 37.1° showed that MC-CDs possessed monolayer crystal structure. The crystal plane 101 at 2θ = 45.3° indicated that MC-CDs have hexagonal structure. We then measured the zeta potential of MC-CDs and found that the value was negative charge −25.20 mV (Figure 2H), demonstrating its stability and biocompatible.

To gain a better insight into the organic functional groups on the surface of the MC-CDs, we further analyzed the MC-CDs using FTIR (Figure 2F). The peaks in the IR spectra were assigned according to the Sadtler Handbook of Infrared Spectra. The character absorption bands at 3548, 3474 cm⁻¹ ascribable to hydroxyl groups, and 3410, 3236 cm⁻¹ represent stretching vibrations of amino groups (N-H); The typical stretching vibrations of C=O and C=C could be observed at 1776, 1639 and 1618 cm⁻¹; The peak located at 1385 cm⁻¹ can be attributed to stretching vibrations of ester groups, and the peak at 1137 cm⁻¹ was due to the asymmetric and symmetric stretching vibrations of C-O or C-N groups.

The surface chemical properties and characteristics of the MC-CD functional groups were determined using XPS. As shown in Figure 3A, the three peaks of the full-survey XPS at 285.0, 400.0 and 533.0 eV correspond to C1s, O1s, and N1s, respectively. This spectral result exhibited that the MC-CDs are composed of carbon, oxygen, and nitrogen with atomic percentages of 63.38%, 34.47% and 2.16%, respectively. In the high-resolution C1s spectrum, three different peaks correspond to carbon for C-C/C=C (284.8 eV), C-O (286.4 eV), and O-C=O (288.5 eV) (Figure 3B). The high-resolution O1s spectrum indicated different chemical environments of C=O (531.8 eV), and C-O (532.9 eV) (Figure 3C). Moreover, the peaks in the high-resolution scans of the N1s region correspond to nitrogen for C-N at 399.9 eV, and N-(C)3 at 401.1 eV (Figure 3D).

To further characterize the products, the luminescence properties of MC-CDs were evaluated. The fluorescence emission spectrum of the prepared MC-CDs exhibited the strongest peak at 440 nm upon excitation at 340 nm (Figure 4A). Figure 4B shows the excitation spectra of MC-CDs at emission wavelengths progressively increasing from 300 to 340 nm and decreasing from 360 to 460 nm. Figure 4C shows the emission spectra of MC-CDs at excitation wavelengths progressively increasing from 400 to 440 nm and decreasing from 460 to 560 nm.

Cytotoxicity Evaluation of MC-CDs
To investigate the safety of the MC-CDs, their cytotoxicity was evaluated in HT-22 cells. As shown in Figure 5, even when the concentration of MC-CDs reached up to 640 μg/mL, the cell viability was still greater than 90%, even when the concentration of MC-CDs reached 640 μg/mL. MC-CDs significantly increased the viability of MDA-MB-231 cells in a dose-dependent manner (1.25–80 μg/mL), indicating that MC-CDs promoted cell growth. These results indicate that MC-CDs could be bio-safe in normal cells.
Solubility Study

In this study, an HPLC method was established and validated for the determination of MA in an MC-CDs aqueous solution. The solubility of MA in water was 115.46 μg/mL, and the linear equation was $y = 21,863.4253x - 17,396.5833$ with $r = 1.0000$. As shown in Figure 6, the concentration of MA increased with increasing concentrations of MC-CDs. The RSD values of the peak area and retention time of the samples were calculated methodologically; the RSD value of the peak area of the precision was 0.09%, the RSD value of the retention time was 0.22%, the RSD value of the stability peak area was 1.10%, the RSD value of the retention time was 1.31%, the reproducible peak area RSD value was 2.92%, the retention time RSD value was 2.49%, and the recovery rate of the sample was 100.68%~102.78%; It shows that the proposed method was good and the prepared samples were relatively stable.
Pharmacokinetic Evaluation

Taking the square of the MA peak area as the abscissa, the linear equation was $y = 4611.325x + 13,765.59393$ ($r = 0.9589$). The recovery rate of this method was more than 80%, the matrix effect was greater than 82%, the accuracy was between 111%-132%, the intraday precision was 4.42%, the intraday precision was 5.25%, and the stability was approximately 4.92%, indicating that the results obtained by this method were stable and reliable. The mean MA concentration-time curve is shown in Figure 7, and the main pharmacokinetic parameters are summarized in Table 1. Significantly different pharmacokinetic behaviors were observed between the MA control and MA-MC-CDs. The concentration of MA in rats treated with different concentrations of MA-MC-CDs was much higher than that of the
MA control before 2.5 h, and the concentration of MA from MA-MC-CDs was lower than that of the MA control after 2.5 h, indicating that MA was rapidly absorbed and released into the bloodstream with the help of the MC-CDs.

The peak concentration $C_{\text{max}}$ value of the MA from MA control and MA-MC-CDs in rats was 201.28 ± 31.38 ng/L and 323.98 ± 82.21 ng/L, respectively, compared to those of the control and MA-MC-CDs in rats was 4.00 ± 1.42 h and 0.25 ± 0.76 h, respectively. The $t_{1/2}$ value of the MA from MA control and MA treated with MC-CDs in rats was 3.27 ± 2.18 h and 7.22 ± 2.47 h, respectively. The CL/F value of the MA from MA control and MA treated with MC-CDs in rats was 11,144.46 ± 4039.27 L/h/kg and 14,490.30 ± 3335.50 L/h/kg, respectively. The AUC$_{0-\text{t}}$ value

Figure 5 Cytotoxicity in HT-22 cells. All data are presented as the mean ± SD. *$p < 0.05$, **$p < 0.01$ between two groups.

Figure 6 Concentration profiles of MA in the aqueous MC-CDs solutions.

MA control before 2.5 h, and the concentration of MA from MA-MC-CDs was lower than that of the MA control after 2.5 h, indicating that MA was rapidly absorbed and released into the bloodstream with the help of the MC-CDs.

The peak concentration $C_{\text{max}}$ value of the MA from MA control and MA-MC-CDs in rats was 201.28 ± 31.38 ng/L and 323.98 ± 82.21 ng/L, respectively, compared to those of the control and MA-MC-CDs in rats was 4.00 ± 1.42 h and 0.25 ± 0.76 h, respectively. The $t_{1/2}$ value of the MA from MA control and MA treated with MC-CDs in rats was 3.27 ± 2.18 h and 7.22 ± 2.47 h, respectively. The CL/F value of the MA from MA control and MA treated with MC-CDs in rats was 11,144.46 ± 4039.27 L/h/kg and 14,490.30 ± 3335.50 L/h/kg, respectively. The AUC$_{0-\text{t}}$ value
of the MA from MA control and MA treated with MC-CDs in rats was 1523.45 ± 2638.01 ng/L·h and 1249.81 ± 186.09 ng/L·h, respectively. In addition, the MRT value of MA from MA-MC-CDs was greater than that of the MA control. Collectively, these data revealed that MC-CDs effectively affected the pharmacokinetic parameters of MA in rats.

Discussion

MC-CDs have loose texture and good water solubility at 1–5 nm, and it can be found that when the concentration of MC-CDs exceeds 100 μg/mL, the solubility of MA in water increases significantly with the increase of MC-CDs concentration.

In a preliminary experiment on rat pharmacokinetics, methanol, acetonitrile, and acetonitrile-glacial acetic acid-precipitated protein were also investigated, and it was found that the recovery rate of plasma treated with acetonitrile-glacial acetic acid was high, in line with the requirements. After reviewing the literature, it was found that when the concentration of acetonitrile exceeded 1000 ng/mL, there was ion suppression, resulting in low extraction recovery.53

Table 1 Pharmacokinetic Parameters of MA in Rats After Oral Administration of MA Control and MA-MC-CDs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unit</th>
<th>MA</th>
<th>MA-MC-CDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax</td>
<td>ng/L</td>
<td>201.28 ± 31.38</td>
<td>323.98 ± 82.21</td>
</tr>
<tr>
<td>Tmax</td>
<td>h</td>
<td>4.00 ± 1.42</td>
<td>0.25 ± 0.76</td>
</tr>
<tr>
<td>t1/2</td>
<td>h</td>
<td>3.27 ± 2.18</td>
<td>7.22 ± 2.47</td>
</tr>
<tr>
<td>CL/F</td>
<td>L/h/kg</td>
<td>11,144.46 ± 4039.27</td>
<td>14,490.30 ± 3335.50</td>
</tr>
<tr>
<td>AUC0-t</td>
<td>ng/L·h</td>
<td>1523.45 ± 2638.01</td>
<td>1249.81 ± 186.09</td>
</tr>
<tr>
<td>MRT0-t</td>
<td>h</td>
<td>5.23 ± 0.60</td>
<td>5.96 ± 1.55</td>
</tr>
</tbody>
</table>
Due to the poor oral absorption of MA, the maximum concentration was 200 ng, so the detection method of UPLC-MS/MS was established. This method has short analysis time, high sensitivity, and good detection results for low-content components.

It can be seen from the literature that the $C_{\text{max}}$ of MA is low, and the $T_{\text{max}}$ after oral administration is about $267.49 \pm 108.29$ min, which is basically consistent with the results of this experiment.\textsuperscript{54} The addition of MC-CDs can increase the content of MA in vivo, shorten the time to reach the maximum concentration, extend the half-life of MA, and increase the apparent volume. To promote the absorption of drugs in the body, the onset time should be shortened to maintain efficacy so that the drugs can enter organs and tissues from the blood vessels faster.\textsuperscript{55}

Our study shows that the novel carbon dots derived from natural *Moutan Cortex* significantly improve the solubility and bioavailability of mangiferin, which indicating its potential as a drug delivery system to improve the biopharmaceutical properties of other insoluble drugs. Several researches also supported the enormous promise of nanoparticles derived from natural sources.\textsuperscript{56-58} In particular, the carbon dots from natural sources as the only source would possess infinite opportunities in the pharmaceutical and bio-technological industry.

**Conclusion**

*Moutan Cortex*-derived novel CDs exhibited excellent performance in improving the solubility and bioavailability of MA. The results of the CCK-8 assay showed that the MC-CDs have low cytotoxicity and can be used in various organisms. Because it contains -OH and -NH, it can form intramolecular hydrogen bonds with the phenolic hydroxyl groups of MA to increase the solubility of MA, and the formation of complex junction stability increases the content of MA in vivo, and the peak time is advanced from 4 h to 0.25 h. This study not only opens new possibilities for the future clinical application of MA but also provides evidence for the development of green biological carbon dots as a drug delivery system to improve the biopharmaceutical properties of insoluble drugs.

**Data Sharing Statement**

The data supporting the findings of this study are available upon request from the corresponding author.

**Ethics Approval**

All experiments and procedures were performed according to the animal study protocol approved by the Animal Care Ethics Committee of Anhui University of Chinese Medicine. All experiments were performed in accordance with the Guidelines for Ethical Conduct in the Care and Use of Animals.

**Acknowledgments**

We acknowledge the support from the Department of Material Science and Information Technology, Anhui University.

**Funding**

This work was supported by the Natural Science Foundation of Anhui Province (2308085MH304), the National Natural Science Foundation of China (82304324), the Research Foundation of Education Bureau of Anhui Province (2022AH050472, 2023AH040101), and the High-level Talents Support Project of Anhui University of Chinese Medicine (2022rczd011).

**Disclosure**

The authors declare that they have no conflicts of interest in this work.

**References**


